ArticleFrontiers in immunology2026
Clinical characteristics and renal risk stratification of mixed-type IgA vasculitis: a large-volume study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mixed-type IgA vasculitis (IgAV) is common in clinical practice, but its internal heterogeneity and prognostic significance, especially in renal involvement, remain unclear. This study aimed to characterize mixed-type IgAV, compare renal risk across mixed subtypes, and evaluate the additional predictive value of mixed subtype classification for clinically significant renal involvement. Methods: We performed a retrospective cohort study of patients with clinically diagnosed IgAV treated between December 2018 and October 2025. Among 2,818 admissions/records screened, 2,416 unique patients were included after excluding repeated admissions, including 739 non-mixed and 1,677 mixed-type cases. Mixed type and mixed subtypes were defined according to organ involvement at first admission. Clinically significant renal involvement was defined from discharge diagnoses and renal-related clinical documentation, with available renal laboratory indicators used as supporting evidence. Laboratory-based component and sensitivity analyses were additionally performed using predefined proteinuria, eGFR, and serum creatinine criteria. Subtype-specific logistic regression, receiver operating characteristic (ROC) analysis, and a visit-order KM-like proteinuria analysis were performed. Results: Compared with non-mixed disease, mixed-type IgAV was associated with lower BMI and albumin, higher white blood cell and platelet counts, longer hospital stay, and markedly higher frequencies of digestive, joint, and renal involvement. Within the mixed-type cohort, clinically significant renal involvement varied substantially across subgroups, ranging from 26.7% to 76.9%. Using Skin-Joint as the reference group, significantly higher odds of clinically significant renal involvement were observed in the Other/rare group, Skin-Renal, Skin-Joint-Renal, and Skin-Abdominal-Renal (all Conclusions: Mixed-type IgAV is a heterogeneous phenotype with marked subtype-dependent differences in renal risk. Mixed subtype classification improves identification of clinically significant renal involvement and may support earlier and more individualized renal risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.